<DOC>
	<DOCNO>NCT02793310</DOCNO>
	<brief_summary>The purpose study determine whether corneal transplantation Descemet Membrane Endothelial Keratoplasty favourable cost-effective compare Descemet Stripping Automated Endothelial Keratoplasty Fuchs Endothelium Corneal Dystrophy .</brief_summary>
	<brief_title>DMEK Versus DSAEK Study</brief_title>
	<detailed_description>FECD progressive , multifactorial irreversible disease characterize accelerated loss corneal endothelial cell innermost layer cornea lead vision impairment potential blindness leave untreated . FECD responsible 50 % 1.300 annual corneal transplantation Netherlands . Corneal transplantation improve vision quality life patient corneal disease . Currently , standard care patient Fuchs Endothelial Corneal Dystrophy ( FECD ) Descemet Stripping Automated Endothelial Keratoplasty ( DSAEK ) , posterior layer cornea transplant . However , visual recovery follow DSAEK suboptimal . Descemet Membrane Endothelial Keratoplasty ( DMEK ) , late technique corneal transplantation involve transplantation monolayer corneal endothelium Descemet 's membrane provide thin endothelial graft possible . DMEK suggest result faster well visual recovery compare DSAEK . While economic burden , medical social , disease assess date , cost associate corneal transplantation reach $ 110 million dollar yearly 47.000 transplantation USA . The objective project assess effect cost DMEK vs. DSAEK order determine whether new technique effective cost-effective standard technique . The primary outcome measure best-corrected visual acuity . Secondary outcome measure contrast acuity , astigmatism , quality vision , endothelial cell loss , incidence graft rejection , primary graft failure , cornea donor loss due preparation , generic vision-related quality life .</detailed_description>
	<mesh_term>Fuchs ' Endothelial Dystrophy</mesh_term>
	<criteria>Cornea decompensation cause Fuchs Endothelial Corneal Dystrophy Ocular comorbidities cataract Previous corneal transplantation Human leukocyte antigen ( HLA ) match keratoplasty Inability complete followup</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>